Merck (MRK) Income from Continuing Operations (2009 - 2026)
Merck (MRK) posted quarterly Income from Continuing Operations of 4209000000.0 for Q1 2026, down 182.77% year-over-year from 5085000000.0 in Q1 2025, and down 242.1% quarter-over-quarter from 2962000000.0 in Q4 2025.
Merck (MRK) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Income from Continuing Operations for 18 consecutive years, with 4209000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 182.77% year-over-year to 4209000000.0; the TTM figure through Mar 2026 stood at 8968000000.0 (down 48.61% YoY), while the FY2025 annual figure was 18263000000.0, up 6.6% from the prior year.
- Income from Continuing Operations fell to 4209000000.0 in Q1 2026 per MRK's latest filing, from 2962000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5787000000.0 in Q3 2025 and bottomed at 5972000000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 2711176470.59 across 5 years, with a median of 3744000000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 251.23% — and 2024, when it soared 405.38%.
- Merck's Income from Continuing Operations stood at 3018000000.0 in 2022, then tumbled by 140.62% to 1226000000.0 in 2023, then jumped by 405.38% to 3744000000.0 in 2024, then slipped by 20.89% to 2962000000.0 in 2025, then sank by 242.1% to 4209000000.0 in 2026.
- Business Quant data shows MRK's Income from Continuing Operations at 4209000000.0 in Q1 2026, 2962000000.0 in Q4 2025, and 5787000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.34 Bn |
| Mar 31, 2026 | -4.21 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.97 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2022 | 3.02 Bn |
| Sep 30, 2022 | 3.25 Bn |
| Jun 30, 2022 | 3.95 Bn |
| Mar 31, 2022 | 4.31 Bn |
| Dec 31, 2021 | 3.82 Bn |
| Sep 30, 2021 | 4.57 Bn |